ARB Starting Dose in End-Stage Renal Disease on Hemodialysis
In patients with end-stage renal disease on hemodialysis, ARBs should generally be avoided or used with extreme caution, as the KDIGO 2024 guidelines recommend considering dose reduction or discontinuation when eGFR <15 ml/min per 1.73 m² to reduce uremic symptoms. 1
Clinical Context and Guideline Framework
The KDIGO 2024 guidelines provide clear direction that ARBs (and ACE inhibitors) should be considered for dose reduction or discontinuation in kidney failure (eGFR <15 ml/min per 1.73 m²) 1. This recommendation specifically addresses the population you're asking about—patients on regular hemodialysis who by definition have end-stage renal disease.
Key Considerations Before Starting
Practice Point 3.6.5 explicitly states: Consider reducing the dose or discontinuing ACEi or ARB in the setting of uremic symptoms while treating kidney failure (eGFR <15 ml/min per 1.73 m²) 1. This suggests that if you're initiating therapy in a dialysis patient, you should:
- Start at the lowest available dose of the chosen ARB
- Have a compelling indication (e.g., heart failure with reduced ejection fraction, uncontrolled hypertension despite volume management)
- Ensure volume status is optimized first, as volume control represents the principal strategy for hypertension management in ESRD 2
Specific Dosing Approach
If ARB Initiation is Deemed Necessary:
Start with the lowest commercially available dose:
- Losartan 25 mg daily (or after dialysis on dialysis days)
- Valsartan 40 mg daily (or after dialysis on dialysis days)
- Candesartan 4 mg daily (or after dialysis on dialysis days)
These three ARBs were specifically studied in hemodialysis patients 3, though the study used them without specific dose recommendations for initiation.
Timing of Administration:
Administer after dialysis sessions on dialysis days, as ARBs are generally not significantly dialyzable 4. This approach:
- Minimizes intradialytic hypotension risk
- Provides more stable drug levels
- May improve medication adherence (thrice-weekly dosing after dialysis) 2
Monitoring Protocol
Within 2-4 weeks of initiation, check: 1
- Blood pressure (both pre- and post-dialysis)
- Serum potassium
- Residual renal function (if any)
Continue therapy only if: 1
- No symptomatic hypotension develops
- Hyperkalemia remains controllable
- Patient tolerates the medication
Critical Pitfalls to Avoid
Don't assume ARBs are first-line in dialysis patients - Unlike earlier CKD stages where ARBs are strongly recommended for proteinuria 1, the benefit-risk ratio shifts dramatically in ESRD on dialysis
Don't use standard CKD dosing - The guideline's Practice Point 3.6.1 states ARBs should be given at "highest approved dose that is tolerated" 1, but this applies to CKD G1-G4, not G5D (dialysis patients)
Don't ignore volume status - Hypertension in dialysis patients is primarily volume-mediated; adding ARBs without addressing volume overload is futile and potentially harmful 2
Don't combine with ACE inhibitors - Dual RAS blockade is explicitly contraindicated 1
Evidence Quality and Nuances
The 2024 KDIGO guidelines 1 represent the highest quality evidence available, though they notably soften recommendations for ARB use as kidney function declines. The only randomized trial in hemodialysis patients 3 showed cardiovascular benefit with ARBs (hazard ratio 0.51), but this was a small open-label study with potential for spurious findings, as the authors themselves acknowledged.
The pharmacokinetic literature 4 notes that ARBs are not dialyzable, which distinguishes them from some ACE inhibitors but also means drug accumulation is a concern in anuric patients.
The practical reality: Most dialysis patients who are hypertensive should first undergo aggressive ultrafiltration and sodium restriction. Only after optimizing dry weight should ARBs be considered, and then only at minimal doses with close monitoring for hypotension and hyperkalemia.